奧洛茲美醫療 HALO 深 滬
已收盤 12-19 16:00:00 美东时间
67.35
+2.240
+3.44%
華盛通- 最 高67.53
- 今 開65.28
- 成交量 325.73万股
- 最 低 65.11
- 昨 收 65.11
- 總市值 78.80亿
- 52周最高 79.50
- 市盈率 靜 19.63
- 換手率 2.78%
- 52周最低 47.50
- 委 比 -35.64%
- 總股本 1.17亿
- 歷史最高 79.50
- 量 比 1.23
- 振 幅 3.72%
- 歷史最低 3.86
- 每 手 1
- 風險率 7.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Halozyme Says FDA Approves Johnson & Johnson's Five-Minute Injection Version Of Lung Cancer Drug RYBREVANT
Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and
12-18 20:07
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
12-17 02:17
Halozyme Approves Stock Grant for CEO Incentive
An update from Halozyme ( ($HALO) ) is now available. On December 4, 2025, Halo...
12-10 06:17
Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than ...
12-09 05:05
Halozyme Therapeutics Granted Preliminary Injunction From German Court Against Merck's Keytruda
Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in
12-05 02:30
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
12-01 14:33
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $90 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $90 price target.
11-28 20:11
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $56
Goldman Sachs analyst Graig Suvannavejh maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $54 to $56.
11-19 01:56
